KR102165246B1 - 안과 치료제 - Google Patents

안과 치료제 Download PDF

Info

Publication number
KR102165246B1
KR102165246B1 KR1020187038197A KR20187038197A KR102165246B1 KR 102165246 B1 KR102165246 B1 KR 102165246B1 KR 1020187038197 A KR1020187038197 A KR 1020187038197A KR 20187038197 A KR20187038197 A KR 20187038197A KR 102165246 B1 KR102165246 B1 KR 102165246B1
Authority
KR
South Korea
Prior art keywords
eye
composition
tramadol
ophthalmic
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187038197A
Other languages
English (en)
Korean (ko)
Other versions
KR20190004815A (ko
Inventor
아난트 샤르마
Original Assignee
옵토솔브 리서치 앤드 디벨롭먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105732.0A external-priority patent/GB201105732D0/en
Priority claimed from GBGB1105731.2A external-priority patent/GB201105731D0/en
Application filed by 옵토솔브 리서치 앤드 디벨롭먼트 리미티드 filed Critical 옵토솔브 리서치 앤드 디벨롭먼트 리미티드
Publication of KR20190004815A publication Critical patent/KR20190004815A/ko
Application granted granted Critical
Publication of KR102165246B1 publication Critical patent/KR102165246B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187038197A 2011-04-05 2012-04-05 안과 치료제 Active KR102165246B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1105731.2 2011-04-05
GBGB1105732.0A GB201105732D0 (en) 2011-04-05 2011-04-05 Ophthalmic lubricants
GB1105732.0 2011-04-05
GBGB1105731.2A GB201105731D0 (en) 2011-04-05 2011-04-05 Topical analgesics
PCT/GB2012/000330 WO2012136969A2 (en) 2011-04-05 2012-04-05 Ophthalmic treatments

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029016A Division KR20140145948A (ko) 2011-04-05 2012-04-05 안과 치료제

Publications (2)

Publication Number Publication Date
KR20190004815A KR20190004815A (ko) 2019-01-14
KR102165246B1 true KR102165246B1 (ko) 2020-10-13

Family

ID=46086008

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187038197A Active KR102165246B1 (ko) 2011-04-05 2012-04-05 안과 치료제
KR1020137029016A Ceased KR20140145948A (ko) 2011-04-05 2012-04-05 안과 치료제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137029016A Ceased KR20140145948A (ko) 2011-04-05 2012-04-05 안과 치료제

Country Status (12)

Country Link
US (2) US20140088199A1 (enExample)
EP (2) EP2694048B1 (enExample)
JP (2) JP6148664B2 (enExample)
KR (2) KR102165246B1 (enExample)
CN (2) CN103687594A (enExample)
BR (1) BR112013025493A2 (enExample)
CA (1) CA2869280C (enExample)
ES (1) ES2836808T3 (enExample)
HK (1) HK1254720A1 (enExample)
MA (1) MA35070B1 (enExample)
MX (1) MX346312B (enExample)
WO (1) WO2012136969A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
GB201217522D0 (en) * 2012-10-01 2012-11-14 Sharma Anant ophthalmic therapy
WO2014167327A1 (en) * 2013-04-09 2014-10-16 Cresset Biomolecular Discovery Ltd The treatment of inflammatory disorders
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
JP2017502089A (ja) * 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016022066A1 (en) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
AU2016222902A1 (en) * 2015-02-24 2017-08-31 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
ES2604816B1 (es) 2015-09-09 2018-01-29 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
PT3842047T (pt) * 2015-09-24 2024-09-19 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
WO2017059088A1 (en) * 2015-09-30 2017-04-06 George Edward Hoag Topical analgesic pain relife formulations, manufacture and methods of use thereof
CN105232449B (zh) * 2015-10-30 2019-04-09 上海昊海生物科技股份有限公司 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法
EP4241759A1 (en) * 2016-10-12 2023-09-13 PS Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
WO2018212846A1 (en) 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
MY205909A (en) * 2017-06-08 2024-11-20 Eye Therapies Llc Low-dose brimonidine combinations and uses thereof
KR20250065422A (ko) 2017-12-15 2025-05-12 타르서스 파마수티칼스, 아이엔씨. 안검염을 치료하기 위한 이속사졸린 구충제 제제 및 방법
MX2018003456A (es) 2017-12-21 2019-09-06 Gruenenthal Gmbh Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
CN111886001A (zh) * 2018-03-13 2020-11-03 参天制药株式会社 滴眼型洗眼药用组合物
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220265695A1 (en) 2019-07-26 2022-08-25 Proqr Therapeutics Ii B.V. Opthalmic compositions comprising viscosifying polymers and nucleic acids
US11504269B2 (en) 2019-11-19 2022-11-22 Jennifer L. Fabian Therapeutic bra
WO2021163304A1 (en) * 2020-02-11 2021-08-19 Tufts Medical Center, Inc. Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
CN112007028A (zh) * 2020-09-03 2020-12-01 北京博纳致恒科技有限责任公司 一种复合睫状肌松弛剂的人工泪液及用途
EP4297741A4 (en) * 2021-02-26 2025-02-26 Vyluma Inc. METHODS AND FORMULATIONS FOR TOPICAL ADMINISTRATION OF GABAPENTINOIDS
WO2023285878A1 (en) * 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
EP4534081A1 (en) * 2022-07-06 2025-04-09 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
TW202408474A (zh) * 2022-07-06 2024-03-01 學校法人金澤醫科大學 疼痛抑制劑
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
JPWO2024010040A1 (enExample) * 2022-07-06 2024-01-11
WO2025146828A1 (ja) * 2024-01-05 2025-07-10 ロート製薬株式会社 眼科組成物
WO2025159099A1 (ja) * 2024-01-24 2025-07-31 国立大学法人北海道大学 医薬組成物、眼瞼けいれん処置薬、知覚過敏またはジストニア処置薬、および症状モデルマウス

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022663A1 (en) * 1995-11-14 2002-02-21 Mark Alfonso Formulation for respiratory tract administration
WO2005117830A1 (en) 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
US20060008506A1 (en) * 2004-06-28 2006-01-12 Cipriano De Sousa Herminio J Method for preparing therapeutic ophthalmic articles using compressed fluids
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384043B1 (en) 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
ATE214272T1 (de) * 1996-12-16 2002-03-15 Alcon Lab Inc Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
JP2004143157A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 点眼剤
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20090010850A1 (en) 2007-05-24 2009-01-08 Ousler Iii George W Formulations and methods for treating dry eye
CA2636646A1 (en) * 2006-01-25 2007-08-02 Aciex, Inc. Formulations and methods for treating dry eye
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022663A1 (en) * 1995-11-14 2002-02-21 Mark Alfonso Formulation for respiratory tract administration
WO2005117830A1 (en) 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
US20060008506A1 (en) * 2004-06-28 2006-01-12 Cipriano De Sousa Herminio J Method for preparing therapeutic ophthalmic articles using compressed fluids
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol

Also Published As

Publication number Publication date
KR20190004815A (ko) 2019-01-14
US9913813B2 (en) 2018-03-13
JP2017141243A (ja) 2017-08-17
US20140088199A1 (en) 2014-03-27
US20160199320A1 (en) 2016-07-14
CA2869280C (en) 2020-03-10
JP2014513073A (ja) 2014-05-29
ES2836808T3 (es) 2021-06-28
HK1254720A1 (zh) 2019-07-26
CN107982211A (zh) 2018-05-04
CA2869280A1 (en) 2012-10-11
BR112013025493A2 (pt) 2017-03-01
WO2012136969A3 (en) 2013-01-03
JP6419876B2 (ja) 2018-11-07
CN103687594A (zh) 2014-03-26
WO2012136969A2 (en) 2012-10-11
MX2013011314A (es) 2014-03-27
MX346312B (es) 2017-03-15
EP3799866A1 (en) 2021-04-07
EP2694048B1 (en) 2020-10-07
KR20140145948A (ko) 2014-12-24
MA35070B1 (fr) 2014-04-03
EP2694048A2 (en) 2014-02-12
JP6148664B2 (ja) 2017-06-14

Similar Documents

Publication Publication Date Title
KR102165246B1 (ko) 안과 치료제
CA2880027C (en) Progesterone compositions and treatment for eye diseases and disorders
ES2812532T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir la rosácea
US8530449B2 (en) Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
JP2014513073A5 (enExample)
MX2014006804A (es) Administración eficiente de lipidos a la pelicula lagrimal humana mediante el uso de un sistema de emulsión sensible a la sal.
JP2001521500A (ja) 緑内障に関連する視神経変性を防止する薬剤の製造におけるナトリウムチャンネル遮断剤の使用
KR20220011691A (ko) 안 질환의 치료
CN116437910A (zh) 含有西替利嗪和托可索仑的眼用组合物
JP4475802B2 (ja) 緑内障の局所治療用フルナリジンの使用法
US9187468B2 (en) Topical ocular analgesic agents
RU2772357C2 (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
Gerding Update on practical ocular pharmacology.
HK1210968B (en) Compositions and treatment for eye diseases and disorders

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6